## Hao Li

## List of Publications by Citations

Source: https://exaly.com/author-pdf/8537220/hao-li-publications-by-citations.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26 138 8 10 g-index

29 205 4.3 2.65 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
26	H+/K+-ATPase inhibitors: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , <b>2013</b> , 23, 99-111	6.8	26
25	Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 576	5.6	18
24	Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 1066	5.6	12
23	Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60/ADR cells via inhibition of the PI3K/Akt signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , <b>2020</b> , 125, 109885	7.5	12
22	Integrin inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2018, 28, 903-917	6.8	9
21	Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With and Genetic Defect. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 491	5.6	8
20	Novel oxytocin receptor agonists and antagonists: a patent review (2002 - 2013). <i>Expert Opinion on Therapeutic Patents</i> , <b>2014</b> , 24, 29-46	6.8	8
19	Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions. <i>Drugs in R and D</i> , <b>2012</b> , 12, 65-70	3.4	8
18	A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti- Integrin Monoclonal Antibody. <i>Current Drug Metabolism</i> , <b>2018</b> , 19, 1213-1223	3.5	7
17	Identification of microRNA biomarkers in atrial fibrillation: A protocol for systematic review and bioinformatics analysis. <i>Medicine (United States)</i> , <b>2019</b> , 98, e16538	1.8	6
16	Impact of Gastric rs2733743 on the Intragastric pH-Values of Dexlansoprazole Injection in Chinese Subjects. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 670	5.6	4
15	Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis. <i>Medicine (United States)</i> , <b>2018</b> , 97, e0420	1.8	3
14	Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	3
13	The Management of Heavy Menstrual Bleeding After Percutaneous Coronary Intervention in a Woman of Reproductive Age. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1573	5.6	2
12	The Successful Rapid Adjustment of Blood Glucose in a Patient With Acute Coronary Syndrome, Renal Insufficiency, and Diabetes: A Case Report of Management Coordinated by Clinical Pharmacists and Clinicians. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 756	5.6	2
11	Molecular evolution of the vertebrate FK506 binding protein 25. <i>International Journal of Genomics</i> , <b>2014</b> , 2014, 402603	2.5	2
10	Intervention by clinical pharmacists can improve blood glucose fluctuation in patients with diabetes and acute myocardial infarction: A propensity score-matched analysis. <i>Pharmacology Research and Perspectives</i> , <b>2021</b> , 9, e00725	3.1	2

## LIST OF PUBLICATIONS

9	Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails. <i>Medicine (United States)</i> , <b>2018</b> , 97, e11507	1.8	2
8	High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2125-2136	6.7	1
7	Neutrophil to lymphocyte rate and serum prealbumin maybe predictors for abnormal high blood pressure caused by adrenocorticotropic hormone therapy in children with epileptic spasms: two cases report. <i>Annals of Translational Medicine</i> , <b>2020</b> , 8, 248	3.2	1
6	Clinical adverse effects of sodium-glucose cotransporter 2 inhibitors: Protocol for a systematic review and meta-analysis. <i>Medicine (United States)</i> , <b>2018</b> , 97, e11853	1.8	1
5	Grape seed proanthocyanidin extract induces apoptosis of HL-60/ADR cells via the Bax/Bcl-2 caspase-3/9 signaling pathway <i>Translational Cancer Research</i> , <b>2021</b> , 10, 3939-3947	0.3	0
4	Pharmacokinetics of treprostinil in children with functional single-ventricle pulmonary arterial hypertension: a randomized controlled trial. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 1163	3.2	О
3	Sodium-Glucose Co-Transporter 2 Inhibitors Use Improves the Satisfaction With Anti-diabetic Agent Treatment: A Questionnaire-based Propensity Score-matched Study <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 787704	5.6	
2	Sulfonylureas Use Is Not Associated With Increased Infarct Size in Patients With Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 658059	5.4	
1	Protocol for a systematic evaluation of pediatric pharmacy development and pediatric pharmacy expertsTresearch area in China. <i>Medicine (United States)</i> , <b>2018</b> , 97, e13597	1.8	